Replies to post #57533 on Biotech Values

[DewDiligence]

MRX – Whatever ends up happening with the IP, Solodyn is doomed to being a commercial bust because third-party payers have been reluctant to reimburse for it. Given that the PK difference between Solodyn and ordinary minocycline is small, it’s hard to find fault in the payers’ decisions not to reimburse.

[genisi]

It appears that MRX, knowing that the '838 patent is very weak, filled earlier this year for a new Solodyn formulation, which was not approved yet.